Cargando…
Cardiovascular disease in SARS‐CoV‐2 infection
Pre‐existing cardiovascular disease (CVD) increases the morbidity and mortality of COVID‐19 and is strongly associated with poor disease outcomes. However, SARS‐CoV‐2 infection can also trigger de novo acute and chronic cardiovascular disease. Acute cardiac complications include arrhythmia, myocardi...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8423130/ https://www.ncbi.nlm.nih.gov/pubmed/34512975 http://dx.doi.org/10.1002/cti2.1343 |
_version_ | 1783749401644105728 |
---|---|
author | Sato, Kei Sinclair, Jane E Sadeghirad, Habib Fraser, John F Short, Kirsty R Kulasinghe, Arutha |
author_facet | Sato, Kei Sinclair, Jane E Sadeghirad, Habib Fraser, John F Short, Kirsty R Kulasinghe, Arutha |
author_sort | Sato, Kei |
collection | PubMed |
description | Pre‐existing cardiovascular disease (CVD) increases the morbidity and mortality of COVID‐19 and is strongly associated with poor disease outcomes. However, SARS‐CoV‐2 infection can also trigger de novo acute and chronic cardiovascular disease. Acute cardiac complications include arrhythmia, myocarditis and heart failure, which are significantly associated with higher in‐hospital mortality. The possible mechanisms by which SARS‐CoV‐2 causes this acute cardiac disease include direct damage caused by viral invasion of cardiomyocytes as well as indirect damage through systemic inflammation. The long‐term cardiac complications associated with COVID‐19 are incompletely characterised and thought to include hypertension, arrhythmia, coronary atherosclerosis and heart failure. Although some cardiac‐related symptoms can last over 6 months, the effect of these complications on long‐term patient health remains unclear. The risk factors associated with long‐term cardiovascular disease remain poorly defined. Determining which patients are most at‐risk of long‐term cardiovascular disease is vital so that targeted follow‐up and patient care can be provided. The aim of this review was to summarise the current evidence of the acute and long‐term cardiovascular consequences of SARS‐CoV‐2 infection and the mechanisms by which SARS‐CoV‐2 may cause cardiovascular disease. |
format | Online Article Text |
id | pubmed-8423130 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-84231302021-09-10 Cardiovascular disease in SARS‐CoV‐2 infection Sato, Kei Sinclair, Jane E Sadeghirad, Habib Fraser, John F Short, Kirsty R Kulasinghe, Arutha Clin Transl Immunology Special Feature Review Pre‐existing cardiovascular disease (CVD) increases the morbidity and mortality of COVID‐19 and is strongly associated with poor disease outcomes. However, SARS‐CoV‐2 infection can also trigger de novo acute and chronic cardiovascular disease. Acute cardiac complications include arrhythmia, myocarditis and heart failure, which are significantly associated with higher in‐hospital mortality. The possible mechanisms by which SARS‐CoV‐2 causes this acute cardiac disease include direct damage caused by viral invasion of cardiomyocytes as well as indirect damage through systemic inflammation. The long‐term cardiac complications associated with COVID‐19 are incompletely characterised and thought to include hypertension, arrhythmia, coronary atherosclerosis and heart failure. Although some cardiac‐related symptoms can last over 6 months, the effect of these complications on long‐term patient health remains unclear. The risk factors associated with long‐term cardiovascular disease remain poorly defined. Determining which patients are most at‐risk of long‐term cardiovascular disease is vital so that targeted follow‐up and patient care can be provided. The aim of this review was to summarise the current evidence of the acute and long‐term cardiovascular consequences of SARS‐CoV‐2 infection and the mechanisms by which SARS‐CoV‐2 may cause cardiovascular disease. John Wiley and Sons Inc. 2021-09-07 /pmc/articles/PMC8423130/ /pubmed/34512975 http://dx.doi.org/10.1002/cti2.1343 Text en © 2021 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of Australian and New Zealand Society for Immunology, Inc https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Special Feature Review Sato, Kei Sinclair, Jane E Sadeghirad, Habib Fraser, John F Short, Kirsty R Kulasinghe, Arutha Cardiovascular disease in SARS‐CoV‐2 infection |
title | Cardiovascular disease in SARS‐CoV‐2 infection |
title_full | Cardiovascular disease in SARS‐CoV‐2 infection |
title_fullStr | Cardiovascular disease in SARS‐CoV‐2 infection |
title_full_unstemmed | Cardiovascular disease in SARS‐CoV‐2 infection |
title_short | Cardiovascular disease in SARS‐CoV‐2 infection |
title_sort | cardiovascular disease in sars‐cov‐2 infection |
topic | Special Feature Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8423130/ https://www.ncbi.nlm.nih.gov/pubmed/34512975 http://dx.doi.org/10.1002/cti2.1343 |
work_keys_str_mv | AT satokei cardiovasculardiseaseinsarscov2infection AT sinclairjanee cardiovasculardiseaseinsarscov2infection AT sadeghiradhabib cardiovasculardiseaseinsarscov2infection AT fraserjohnf cardiovasculardiseaseinsarscov2infection AT shortkirstyr cardiovasculardiseaseinsarscov2infection AT kulasinghearutha cardiovasculardiseaseinsarscov2infection |